Using colchicine to reduce heart events in patients after heart artery procedures

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial aims to evaluate the effectiveness of a low dose of colchicine (0.5 mg daily) in reducing cardiovascular events in patients with coronary artery disease (CAD) who have undergone percutaneous coronary intervention (PCI). It is a phase III, randomized, double-blind, multicenter, placebo-controlled trial involving up to 2770 participants. Patients will be randomly assigned to receive either colchicine or a placebo alongside standard medical treatment, with follow-up assessments conducted at regular intervals to monitor outcomes. The study seeks to identify specific patient subgroups that may benefit most from colchicine therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥45 years.
2. Coronary artery disease treated with PCI and optimal medical therapy, with at least one additional risk factor (based on SMART):

   1. Age ≥ year
   2. Diabetes mellitus, on treatment or new diagnosis with HbA1c ≥6.5%
   3. Current smoking
   4. Treated hypertension or lood pressure systolic ≥ 4 mmHg or diastolic ≥ mmHg
   5. Total cholesterol \>240 mg/dl untreated, or treated LDL \>70 mg/dl
   6. HDL \<40 mg/dl
   7. hsCRP \>2 mg/L AND chronic coronary syndrome (CCS)
   8. eGFR \<60 ml/min (MDRD)
   9. history of vascular disease:

      * CAD (PCI prior to index, CABG, MI)
      * stroke (ischemic or hemorrhagic)
      * carotid artery revascularisation
      * PAD (revascularisation, ABI \<0.85 at rest, amputation due to atherosclerotic disease)
      * AAA (repair, distal aortic anteroposterior diameter \>3.0cm)
3. Able to be enrolled/randomized between 2 hour and 5 days post PCI.
4. Written informed consent.

Exclusion Criteria:

1. Women who are pregnant, breastfeeding, or of childbearing potential who are not using an effective method of contraception. Or women who intend to donate oocytes.
2. Men who plan to father children during the study period or who are unwilling to use effective forms of contraception. Or men who intend to donate sperm.
3. Any contraindication or known intolerance to colchicine.
4. Chronic use of -or need for- colchicine.
5. Auto-immune disease or other condition requiring current or planned chronic systemic steroids, immunosuppressant or biologic drug targeting the immune system (for example, TNF blockers, anakinra, rituximab, abatacept, tocilizumab etc.).
6. Creatinine clearance \<30 mL/min/1.73 m2.
7. Cirrhosis Child-Pugh stadium B and C, or acute severe liver disease
8. Neuromuscular disease or non-transient CK levels \> 5 x ULN (unless due to MI).
9. History of cancer or lymphoproliferative disease within the last 3 years, other than successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma, or localized cervix carcinoma in situ.
10. Current or planned use of any strong inhibitor of CYP3A4 or p-glycoprotein: macrolide antibiotics (clarithromycin, telithromycin), azole antifungal agents (ketoconazole, voriconazole, fluconazole, itraconazole), cyclosporine, HIV medication (ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir).
11. Chronic diarrhea, or inflammatory owel disease (Crohn's disease or ulcerative colitis).
12. Drug or alcohol abuse.
13. Planned cardiovascular intervention known on the day of screening.
14. Currently enrolled in another investigational trial.
15. Considered to be an unsuitable candidate by the investigator.

Where it's running

• Algemeen Stedelijk Ziekenhuis Campus Aalst
  Aalst, Belgium Recruiting
• Het Ziekenhuisnetwerk Antwerpen
  Antwerp, Belgium Recruiting
• Universitair Ziekenhuis Antwerpen
  Antwerp, Belgium Recruiting
• Imelda
  Bonheiden, Belgium Recruiting
• AZ Sint-Jan Brugge-Oostende AV
  Bruges, Belgium Recruiting
• Humani Charleroi
  Charleroi, Belgium Recruiting

Study contacts

• Principal investigator: Ian Buysschaert, MD, PhD — ian.buysschaert@azsintjan.be
• Study coordinator: Lisette Van Hove
• Email: Lisette.VanHove@azsintjan.be
• Phone: +32 50 45 39 07

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease

  This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.

  Recruiting Centro Cardiologico Monzino · Cosenza, CS and 3 other locations · NCT07917234

• Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents

  This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.

  Recruiting Adiyaman University · Adıyaman · NCT07898215

• Can preoperative photon-counting CT help predict heart recovery after bypass surgery?

  This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.

  Recruiting Chinese PLA General Hospital · Beijing · NCT07883499

• Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease

  This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.

  Recruiting at 5 sites Hospital Arnau de Vilanova · Mexico City, Mexico City and 4 other locations · NCT07875088

• Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance

  This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.

  Recruiting University of Gaziantep · Gaziantep · NCT07871201

• Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients

  This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.

  Recruiting University of Gaziantep · Gaziantep · NCT07871188

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.